We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biochemical Changes in Stored Donor Units Analyzed

By LabMedica International staff writers
Posted on 12 Jul 2018
Blood transfusion with allogeneic blood products is a common medical intervention to treat anemia or prepare patients for surgical procedures and generally, the blood units are secured and stored prior to expected transfusion.

During storage, several physical and biochemical changes take place in blood products that await transfusion, and the most affected product is whole blood. More...
These changes known collectively as red cell storage lesion are progressive events that affect blood products stored for longer period than products stored for a short period.

Medical Laboratory Scientists at Mbarara University of Science and Technology (Mbarara, Uganda) recruited consecutively a total of 200 blood recipients were categorized into two study arms: group I of 100 received fresh blood and 100 in group II received old blood. A total of 2 mL of venous blood was collected from each participant in EDTA tubes before transfusion for pre-transfusion hemoglobin (Hb) estimation and after transfusion for post-transfusion Hb estimation. Each cross-matched unit was sampled to collect plasma for pH, lactate and potassium assays.

The Hb level was estimated using a Beckman Coulter Diagnostics full hemogram machine; donor lactate level was determined using HumaStar 80; and the potassium and pH in the donor units were determined by Human Diagnostics’ HumaLyte assays. Donor units were cultured in blood agar medium and incubated for 24 hours at 37 °C.

The team reported that the pH of the stored blood dropped from 7.4 to 7.2 in the first three days to ~7.0 by day 11 and to <7.0 by day 35. The mean rise in lactate level was 25 g/dL in blood stored for 0 to 11 days and 32.4 g/dL in blood stored for 21 to 35 days. The highest increase was encountered in blood stored beyond 28 days: 40–57 g/dL by 35 days. Potassium levels equally increased from ~4.6 mmol/L in the first five days of storage to ~14.3 mmol/L by 11 days. From the third week of blood storage and beyond, there was exponential increase in potassium levels, with the highest record in blood units stored from 30 to 35 days.

The authors concluded that whole blood stored for more than 14 days has reduced efficacy with increased markers of red cell storage lesion such as increased potassium level, lactate and fall in pH and these lesions increase the length of hospital stay. The study was published on June 25, 2018, in the Journal of Blood Medicine.

Related Links:
Mbarara University of Science and Technology


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.